PD-1抑制剂(卡瑞利珠单抗)致反应性毛细血管增生症三例并文献复习  

Reactive capillary hemangiomas caused by PD-1 inhibitor (Calerizumab):a report of three cases and literature review

作　　者：龙方园 何芳 涂洁 张致琴 许佳丽[2] 尹志强[1] LONG Fangyuan;HE Fang;TU Jie;ZHANG Zhiqin;XU Jiali;YIN Zhiqiang(Department of Dermatology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China;Department of Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院皮肤科,南京210029 [2]南京医科大学第一附属医院肿瘤科,南京210029

出　　处：《中国麻风皮肤病杂志》2020年第4期219-223,共5页China Journal of Leprosy and Skin Diseases

基　　金：国家自然科学基金面上项目(编号:81673062)。

摘　　要：报道3例实体肿瘤患者经新型PD-1抑制剂(卡瑞利珠单抗)治疗后引起反应性毛细血管增生症并对既往文献进行复习。3例实体肿瘤患者在首次卡瑞利珠单抗治疗后于头颈、四肢或躯干逐渐出现红痣型、珍珠型或桑葚型的血管增生物,皮肤镜检查发现红白均质背景下多个小的边界清晰的红色腔隙,散在分布于皮损区域内。诊断:反应性毛细血管增生症。Three patients with reactive capillary hemangiomas caused by PD-1 inhibitor(calerizumab) treated for solid tumorsed are reported and the related literature is reviewed. After the first treatment with calerizumab, the patients with solid tumors gradually developed to capillary hemangiomas. The lesions were red-nevus-like, pearl-like or mulberry-like, and were most on the head and neck, trunk, and extremities. Dermoscopic examination revealed multiple, small, well-demarcated, red lacunae scattered throughout the lesion on a background of red-whitish homogenous color. The diagnosis of reactive capillary hemangiomas was made.

关 键 词：卡瑞利珠单抗 反应性毛细血管增生症 

分 类 号：R758.25[医药卫生—皮肤病学与性病学] R730.5[医药卫生—临床医学]